0001437749-26-010500
SEC filingRevenue exploded 957% to $1.1M from the Evoke Neuroscience acquisition, driving gross profit to $645K at 56.5% margins, while operating loss improved 12% to -$8.9M through post-rebranding cost discipline, though net loss widened to -$19.9M on non-operating charges.
Operating performance showed discipline amid this pivot. The operating loss improved 12% to -$8.9M from -$10.1M, a meaningful step as the company reduced consultant reliance post-2024 rebranding. This cost control kept operating margins at -775%, still deeply negative but directionally positive, signaling focus on sustainable expense management as revenue base grows. The subscription model in the core business further supports this, encouraging clinics to upgrade tiers with utilization and driving organic expansion without heavy sales pressure.
However, bottom-line results diverged sharply. Net income deteriorated 90% to -$19.9M from -$10.5M, with diluted EPS slipping 23% to -$1.97. Non-operating charges overwhelmed core progress, highlighting risks in a pre-profit neuroscience innovator dependent on external funding and deal dynamics. Cash generation remained a pressure point, with net cash used in operations rising to -$8.2M from -$6.2M. Management attributes this to elevated day-to-day costs, liability paydowns, and R&D investments integrating BNA and Evoke platforms—essential for product evolution but straining liquidity.